In the Mix: 8 More Articles — February 26, 2026

Medterra CBD Review: Products, Testing Standards & Our Experience – Forbes

Medterra markets CBD products with third-party testing documentation available through their website, allowing verification of cannabinoid content and purity profiles. However, the company’s product pages contain limited ingredient transparency, which may complicate clinical assessment of full formulation composition. Certificates of analysis are accessible but require additional steps beyond the product information pages to review detailed testing results. For clinicians considering CBD recommendations to patients, this approach provides some quality assurance through independent testing while presenting a modest barrier to rapid product evaluation. The availability of third-party verification documents represents a reasonable standard for the emerging CBD market, though complete ingredient disclosure on retail pages would better serve evidence-based practice. This review may still be worth reviewing for clinicians seeking practical guidance on evaluating CBD product quality assurance documentation in an industry with variable transparency standards.

R&R CBD Review: Products, Testing Standards & Our Experience – Forbes

R&R CBD manufactures multi-cannabinoid formulations that combine CBD with additional cannabinoids in both THC-containing and THC-free products targeting various therapeutic indications. The Forbes review evaluates the company’s analytical testing standards and product quality metrics relevant to consumers considering cannabinoid-based interventions. While the clinical evidence base for R&R CBD’s specific formulations remains limited, understanding third-party testing protocols and cannabinoid standardization practices across commercial suppliers is relevant for clinicians counseling patients about product selection and safety. The review may provide useful context for practitioners discussing cannabinoid product characteristics with patients already committed to this therapeutic approach.

CBDistillery Review: Products, Testing Standards & Our Experience – Forbes

CBDistillery employs third-party laboratory testing to verify cannabinoid content and potency across its product line, providing consumers with documented cannabinoid concentrations and terpene profiles. The testing protocols ensure transparency regarding the chemical composition of products, which is relevant for patients seeking consistent dosing information. This approach addresses a significant clinical concern regarding cannabinoid product standardization and labeling accuracy, which has been problematic in unregulated markets. While third-party testing does not establish clinical efficacy or safety for specific medical conditions, it represents an important quality control measure that distinguishes some commercial products from untested alternatives. The article may merit clinical attention for healthcare providers seeking to understand quality differentials among over-the-counter cannabinoid products their patients may be considering.

Arizona senator proposes 'public nuisance' bill for marijuana smell – YouTube

An Arizona senator has proposed legislation classifying excessive marijuana odor as a public nuisance, similar to existing regulations for other environmental irritants. The proposal addresses neighbor complaints in residential areas where cannabis use has increased following legalization, though the bill’s enforceability and specific odor measurement standards remain unclear. Stakeholders have expressed concerns about practical implementation, including how to objectively quantify “excessive” odor and the burden on local enforcement agencies. Medical providers may encounter patients reporting olfactory complaints or disputes with neighbors regarding cannabis use, making understanding the regulatory landscape relevant to clinical practice. This legislative approach reflects the ongoing tension between legalization rights and community nuisance concerns that may influence cannabis use patterns and patient counseling in regulated jurisdictions.

The Des – In all, 24 states have passed legislation to legalize marijuana for recreational use …

Twenty-four states have now legalized recreational cannabis, with ongoing expansion in states bordering Iowa and elsewhere. This regulatory shift toward recreational legalization reflects evolving state-level policy landscapes that clinicians should understand when assessing patient cannabis use patterns and availability. The widening legal access may increase prevalence of cannabis use in both recreational and potential self-medication contexts, with implications for screening practices and patient counseling. Healthcare providers should be aware of the legal status in their region and neighboring jurisdictions when discussing cannabis use with patients, as legal access does not eliminate potential health risks or drug interactions. Despite the lower clinical priority of regulatory policy alone, understanding state-level legalization trends remains relevant for contextualizing changing patient cannabis exposure and informing evidence-based counseling about risks regardless of legal status.

Madison Township Zoning Commission OKs site plan for marijuana facility

A zoning commission in Madison Township has approved a site plan for a cannabis cultivation facility, permitting development of a growing operation within township jurisdiction. This regulatory approval reflects ongoing local governance decisions regarding cannabis production infrastructure, which continues to proliferate across various municipalities. The decision represents incremental progress in establishing legal cultivation operations in areas with permissive regulatory frameworks. While individual facility approvals have limited direct clinical implications, they contribute to the broader normalization and accessibility of cannabis supply chains. These local zoning decisions may influence future research access to cultivated cannabis and standardization of growing practices. Clinicians may benefit from monitoring such approvals as they affect local cannabis availability, potency profiles, and product characteristics that patients may be using.

Union County officials seize drugs, candy-branded THC products in multi-agency operation

Law enforcement in Union County executed a coordinated multi-agency operation against unlicensed THC retailers, confiscating products valued at over $100,000 including candy-branded THC items. The enforcement action targeted unauthorized retailers operating outside regulatory frameworks established for cannabis sales. Candy-branded THC products represent a particular public health concern due to their appeal to pediatric populations and increased risk of accidental pediatric ingestion. Such products typically lack proper dosage labeling and quality control standards required in regulated cannabis markets. While this article primarily documents law enforcement activity rather than clinical data, it remains relevant for clinicians who should be aware of the illicit THC product landscape their patients may encounter and the pediatric poisoning risks associated with unregulated, attractively packaged cannabis products.

Here's Why Tenet Healthcare (THC) is a Strong Value Stock – Yahoo Finance

This article is not clinically relevant as it addresses Tenet Healthcare Corporation’s financial performance and stock valuation metrics rather than cannabis pharmacology, cannabinoid therapeutics, or clinical cannabis research. The content focuses on traditional investment analysis including price-to-earnings ratios and market positioning, which have no direct application to medical cannabis practice or cannabinoid science. Healthcare providers and researchers interested in cannabis medicine will find no actionable clinical information regarding cannabinoid mechanisms, drug interactions, dosing strategies, or patient outcomes. The ticker symbol THC appears to be coincidental wordplay rather than substantive engagement with tetrahydrocannabinol or cannabis therapeutics. While this article offers no clinical utility for practitioners or scientists in the cannabis medicine field, it may be worth reviewing if one has financial interests in Tenet Healthcare or seeks to understand how cannabis-adjacent ticker symbols can generate misleading content in financial news feeds.